Get the Stockscreener App
0.3739
0.29%
-0.0011
After Hours:
.37
-0.0039
-1.04%
Soligenix Inc stock is traded at $0.3739, with a volume of 321.86K.
It is down -0.29% in the last 24 hours and down -5.58% over the past month.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
See More
Previous Close:
$0.375
Open:
$0.3734
24h Volume:
321.86K
Relative Volume:
0.05
Market Cap:
$5.54M
Revenue:
$200.00K
Net Income/Loss:
$-10.95M
P/E Ratio:
-0.1894
EPS:
-1.9738
Net Cash Flow:
$-10.78M
1W Performance:
+0.70%
1M Performance:
-5.58%
6M Performance:
-70.09%
1Y Performance:
-87.24%
1-Day Range:
$0.3631
$0.395
1-Week Range:
$0.3506
$0.395
52-Week Range:
$0.28
$6.2299
Soligenix Inc Stock (SNGX) Company Profile
Name
Soligenix Inc
Sector
Industry
Phone
609-538-8200
Address
29 EMMONS DRIVE, PRINCETON
Compare SNGX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
0.3739 | 5.36M | 200.00K | -10.95M | -10.78M | -1.9738 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-20 | Downgrade | Dawson James | Buy → Neutral |
| Jan-31-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-14-17 | Reiterated | Maxim Group | Buy |
| Jul-17-17 | Initiated | H.C. Wainwright | Buy |
Soligenix Inc Stock (SNGX) Latest News
Soligenix Inc (SNGX) Cash Flow - TradingKey
Soligenix Inc (SNGX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Soligenix Inc (SNGX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Soligenix Inc (SNGX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Soligenix Inc (SNGX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Soligenix Inc (SNGX) Institutional Confidence - TradingKey
Soligenix Inc (SNGX) Income Statement - TradingKey
SNGX|Soligenix Inc|Price:0.371|Chg%:-0.002 - TradingKey
Soligenix, Inc. Revenue Breakdown – NASDAQ:SNGX - TradingView
Soligenix (SNGX) seeks reverse stock split and higher authorized shares - Stock Titan
Soligenix (SNGX) Q1 2026 Earnings: Narrower-than-expected net loss per share amid steady pipeline advancement - dars.gov.et
SNGX News | SOLIGENIX INC (NASDAQ:SNGX) - ChartMill
Soligenix (SNGX) seeks reverse stock split, higher share authorization to protect Nasdaq listing - Stock Titan
Soligenix Inc. (SNGX) Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Continued Pipeline Progress - dars.gov.et
Soligenix (SNGX) Q1 2026 Earnings: Narrower-Than-Expected Loss as Pipeline Development ContinuesAnnual Earnings Summary - dars.gov.et
SNGX Stock Price, Quote & Chart - ChartMill
Soligenix Q1 2026 Earnings: Narrower-than-Expected Loss Reflects Cost ManagementAnalyst Drop Coverage - dars.gov.et
Soligenix (SNGX) Q1 2026 Earnings: Small EPS Beat Amid Continued Pipeline ProgressEstimate Dispersion - dars.gov.et
Soligenix, Inc. Financial Disclosures & SEC Filings - TradingView
Soligenix Expands At-the-Market Equity Offering Capacity - The Globe and Mail
SNGX Stock Slumps To Record Low After Lymphoma Trial Fails – All Eyes Now On Behçet’s Disease Treatment - Stocktwits
Form 424B5 Soligenix Inc For: 26 June - Investing.com UK
Form 424B5 Soligenix Inc For: 26 June By Investing.com - Investing.com Nigeria
Soligenix ups ATM offering by $2.5M under Rodman & Renshaw agreement - TradingView
Soligenix (NASDAQ: SNGX) adds $2.5M to at-the-market stock program - Stock Titan
Soligenix (NASDAQ: SNGX) resets ATM capacity to $2.5M under S-3 - Stock Titan
Michael Liu, MJL Manager (SNGX) disclose 983,588 shares; related group holds material blocks - Stock Titan
Soligenix, Inc. Actuals & Estimates (NASDAQ:SNGX) - TradingView
SNGX Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Soligenix, Inc. – NASDAQ:SNGX - TradingView
Price to earnings forward of Soligenix, Inc. – NASDAQ:SNGX - TradingView
SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month On Ebola Vaccine Optimism - Stocktwits
Soligenix (SNGX) Slips 2.31% as Stock Nears Key Support at $0.36Ichimoku Entry - po-news-eg.net
Soligenix Q1 2026 Earnings: Narrower Loss Beats Expectations, No Revenue ReportedBasic EPS Analysis - DonanımHaber
Soligenix Inc (SNGX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Soligenix (SNGX) stock soars 72% on ThermoVax platform promise amid Ebola outbreak caused by Bundibugyo virus - MSN
Soligenix Inc. (SNGX) Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesTax Rate Impact - newsline.com
Soligenix Inc (SNGX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Soligenix Inc (SNGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Soligenix Inc (SNGX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SNGX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionEstimate Revision Count - dars.gov.et
Soligenix Q1 2026 Earnings: Narrower-Than-Expected Loss as EPS Beats EstimatesRevenue Breakdown Analysis - newsline.com
Soligenix (SNGX) Hovers Near Key Support After Modest DeclineBearish Pattern Stocks - newsline.com
Soligenix Halts HyBryte Program, Refocuses Pipeline Strategy - TipRanks
Soligenix's Richard C. Straube ceases Consulting CMO role; duties moved to Christopher Pullion - TradingView
Soligenix (NASDAQ: SNGX) faces Nasdaq bid-price risk and ends HyBryte program - Stock Titan
SNGX Q1 2026 Earnings: EPS Beat Amid No Revenue, Stock DeclinesGross Profit Margin - newsline.com
Soligenix Received Notice of Noncompliance - TradingView
Soligenix (SNGX) Bounces From Support: Biotech Stock Rises 3.5% to $0.44IV Contraction - newsline.com
Soligenix Stock Short Interest Rises to 43.99% - Quiver Quantitative
Soligenix(SNGX) Stock Options Chain | Quotes & News - Moomoo
Soligenix Inc Stock (SNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.44%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):